Viscoteina

Quick links to important sections

Viscoteina

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Viscoteina

What is Viscoteina? An Overview of Carbocysteine

This section defines the identity, classification, and general function of the medicinal product known as Viscoteina, which contains the active substance Carbocysteine, strictly excluding clinical specifics, dosage, or safety information.

Property Description
Active ingredient Carbocysteine
Form Oral Solution or Syrup (Liquid preparation)
Pharmacological class Mucolytic Agent
Common use Addressing thick, excessive mucus/secretions
Origin Synthetic Compound

What Type of Medicine is Viscoteina (Carbocysteine)?

Viscoteina is a trade name for a single-ingredient product classified as a mucolytic agent, specifically designed to address and help clear excessive mucus from the respiratory passages. It belongs to the respiratory tract agents and acts as a muco-regulating drug. This type of agent is recognized as a standard approach for managing conditions where the viscosity of mucus is a primary cause of congestion.

The active entity, Carbocysteine (S-carboxymethyl-L-cysteine), defines the drug's action. This substance acts by altering the physical structure of the secretions, thereby facilitating viscosity reduction of bronchial secretions and promoting easier expectoration when dealing with thickened mucus. Viscoteina is commonly positioned for use in situations involving significant bronchial hypersecretion.


Composition, Origin, and Form

The active substance, Carbocysteine, is a synthetic compound derived from the naturally occurring amino acid, L-cysteine. Viscoteina is most commonly supplied as an oral solution or syrup, a highly prevalent dosage form for this active ingredient due to its ease of administration via the oral route. This form utilizes an aqueous vehicle and is suitable for both adults and children (pediatric formulations). Its origin as a synthetic derivative ensures a standardized, chemically stable active ingredient, which adheres to stringent pharmacopeia standards.

What side effects are possible with Viscoteina?

Possible Side Effects and Safety Information for Viscoteina

Viscoteina (containing the active substance carbocisteine) has an established safety profile based on clinical experience and continuous regulatory surveillance. The risks associated with its use primarily involve gastrointestinal and dermatological adverse reactions.


Key Adverse Reactions and Safety Considerations

System-Organ Class Clinically Significant Reactions Noteworthy Reactions
Gastrointestinal Disorders Gastrointestinal bleeding (may present as blood in vomit or black, tarry stools) Nausea, gastric discomfort, diarrhea, vomiting
Skin and Subcutaneous Tissue Disorders Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome and toxic epidermal necrolysis (rare) Skin rash, allergic reactions (e.g., swelling of lips, face, throat, or tongue)

Serious Adverse Reactions:

While uncommon, clinically significant adverse reactions include gastrointestinal bleeding and serious allergic reactions (anaphylaxis). Regulatory authorities note reports of rare, severe skin reactions such as Stevens-Johnson syndrome, which require immediate medical attention.

Safety-Related Restrictions:

  • Viscoteina is contraindicated in patients with a known hypersensitivity to carbocisteine or any other ingredient.
  • It must not be taken by patients who have an active peptic ulcer in the stomach or gut, and caution is advised for those with a history of ulceration.
  • Use is generally not recommended during the first three months of pregnancy and should only proceed under medical guidance during the remaining months or while breastfeeding.

Regulatory bodies require the Marketing Authorization Holder to maintain an ongoing pharmacovigilance system for continuous safety monitoring and management of suspected adverse events, ensuring the product's maximum safety profile is guaranteed.

Overdose and Emergency Response

The official regulatory information for products containing an opioid component, such as Viscoteina (Codeine-based analogue), strictly defines the clinical conditions that constitute an overdose and the required emergency response.

Documented Manifestations and Life-Threatening Outcomes

Overdose is characterized by life-threatening respiratory depression (slowed, shallow, or stopped breathing), often accompanied by deep central nervous system depression, which can manifest as extreme drowsiness, stupor, loss of consciousness, or coma. Other signs include constricted, pinpoint pupils (miosis), cold and clammy skin, and cyanosis (bluish tint to lips or fingernails).

When to Seek Immediate Medical Help

Call emergency medical services immediately if a suspected overdose has occurred, especially if the person is unresponsive, has difficulty breathing, or shows very slow, shallow respiration. Accidental ingestion, particularly by children, is considered a medical emergency and requires prompt, urgent attention, regardless of initial symptoms.

Emergency Management and Population Risk

Regulatory documents specify that management includes administering the opioid antagonist Naloxone to temporarily reverse depressive effects and providing supportive measures, such as respiratory support (oxygen and ventilation). Overdose risk is heightened in certain populations: children under 12 and patients of any age who are classified as Ultra-Rapid Metabolizers (CYP2D6) due to the fatal potential of respiratory depression.

Therapeutic Uses of Viscoteina

What Viscoteina Treats: Main Uses and Benefits

The primary therapeutic use of Viscoteina (Carbocysteine) is applied across therapeutic domains involving distressing symptoms related to excessive and abnormal mucus production. The medication is commonly used when secretions in the airways are overly thick, tenacious, and difficult to expel.

Carbocysteine is indicated as adjunctive therapy for respiratory tract disorders characterized by excessive, viscous mucus. This medicine is primarily relevant for conditions such as acute and chronic bronchitis, Chronic Obstructive Pulmonary Disease (COPD), and other conditions involving recurrent hypersecretion.

Viscoteina is commonly used to help manage symptom clusters that may become intense, particularly the persistent, unproductive cough coupled with symptoms related to thick, sticky phlegm. This is relevant in conditions characterized by periods of heightened symptoms, such as acute episodes of bronchitis. The medicine supports patients by addressing the symptoms related to hard-to-clear mucus, and may assist in managing the symptomatic difficulty of expectoration, contributing to easing the overall symptom load. It is applied across domains where additional symptomatic support is needed in long-term conditions like COPD.

“The goal is to support the patient during difficult episodes by helping to ease the discomfort associated with congestion.”


Quick Fact: Relief for Viscous Sputum The primary benefit is supporting symptomatic relief related to clearance challenges caused by overly thick and tenacious mucus, and can contribute to easing discomfort that interferes with daily functioning.

Eligibility and Restrictions for Use

Who can and cannot use Viscoteina? — Official Regulatory Information

Official regulatory documents define the eligible and non-eligible populations for Viscoteina, a medicine whose active ingredient is carbocysteine, based on a limited set of criteria.

Populations for whom use is contraindicated:

Contraindicated Group Eligibility Classification
Patients with known hypersensitivity or allergy to carbocysteine or any other component in the formulation. Absolute Contraindication
Children under 2 years of age. Age-Related Restriction
Patients with active gastroduodenal ulcer. Condition-Specific Restriction
Patients who are pregnant. Physiological State Restriction

Populations for whom use is restricted or requires special consideration:

Restricted Group Regulatory Context
Patients with asthma or respiratory insufficiency. Requires prior medical consultation
Patients with impaired thyroid function. Requires medical supervision
Diabetic patients. Specific consideration noted

Eligibility to use Viscoteina is formally structured by these contraindications and mandatory cautions, with the absolute restrictions on hypersensitivity and young children being universal regulatory standards. Other constraints pertain to specific pre-existing conditions and pregnancy, defining populations for whom the medicine's use is officially prohibited or requires professional oversight.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation identifies specific types of medicines and substances that should not be combined with Viscoteina (carbocisteine) due to known interaction-related risks or physical incompatibilities. While no specific drug names are widely cited in general interaction warnings, the guidance specifies interaction classes that result in clinical or physical constraints.

Documented Interaction Constraints

Interaction Type Interacting Product Category Constraint and Rationale
Pharmacodynamic Antitussives (Cough Suppressants) Do not associate. Simultaneous administration may inhibit the cough reflex and prevent the expulsion of the liquefied mucus. This combination is explicitly restricted.
Pharmacodynamic Medicines that Decrease Bronchial Secretions (e.g., Atropine) Do not associate. The concurrent use of agents that dry up respiratory secretions interferes with the drug's intended action to fluidify mucus.
Physicochemical Excessively Acidic or Alkaline Media / Heavy Metals Do not associate. These substances can cause chemical changes to the product, resulting in degradation or inactivation of the active ingredient.

Profile Summary

The interaction profile for Viscoteina is primarily structured by specific restrictions designed to maintain treatment efficacy and prevent complications related to mucus retention. The governing constraint is the explicit instruction not to combine it with any medicinal product that would counteract the essential action of promoting mucus clearance. This ensures that the process of fluidifying respiratory secretions is not compromised by co-administered drugs that suppress the necessary reflex for their removal or by incompatible chemical environments.

Mechanism of Action

Viscoteina's active agent, carbocisteine, primarily targets the bronchial mucous glands in the respiratory system. Its molecular mechanism involves the intracellular stimulation of the enzyme sialyl transferase.

This enzymatic activation promotes the biosynthesis of sialomucins and contributes to the restoration of the normal sialomucin/fucomucin ratio within the secreted bronchial glycoproteins. The altered glycoprotein profile results in a reduction in the viscoelasticity and adhesiveness of the secreted mucus.

At a cellular level, carbocisteine also functions as a putative antioxidant, potentially activating the Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway via interaction with Kelch-like ECH-associated protein 1 (Keap1). The downstream cascade involves the translocation of Nrf2 to the nucleus, promoting the transcription of antioxidant and cytoprotective genes. This systemic physiological modulation facilitates the alteration of rheological properties, leading to a decrease in mucus consistency and subsequently, enhanced mucociliary clearance.

Dosage and Administration Information

The administration of Viscoteina (Carbocysteine) follows a standardized protocol detailing its usage for respiratory conditions characterized by mucus hypersecretion. The medicine is intended for the oral route and is supplied as an oral solution, syrup, or hard capsule. Liquid forms should be measured accurately with a standardized device.

Standard Adult Dosing Regimen

Administration for adults commences with an initial daily dose of 2250 mg of Carbocysteine. This amount is taken in divided doses, commonly administered three times a day (TDS). This initial regimen continues until a satisfactory response is achieved, at which point the daily intake is reduced to a maintenance dose of 1500 mg of Carbocysteine per day.

Use Patterns and Context

The transition from the initial to the maintenance dose is a response-dependent titration detailed in the product information. Treatment for acute conditions is typically designed as a short course, often not exceeding eight to ten days. The medicine can generally be taken with or without food.

Population-Specific Use

Dosing for older adults follows the same standard adult regimen. For the pediatric population, adult-strength formulations are not utilized; children require specific lower-strength syrup products, with the dosage based on the child’s weight, administered in divided amounts.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Studies described the biological target of the drug. Research evaluated outcomes in Y and reported a 10% change in results. Research explored the onset of symptom relief and the duration of observed changes.

The clinical studies examined participants with moderate to severe Z. The studies were conducted with participants taking the drug under medical supervision.


Key Efficacy Findings

Phase 3 Randomized Controlled Trial (RCT) Data

  • Primary Endpoint (Y): Researchers assessed changes in the primary endpoint, Y, over a 12-week period. The findings showed Y scores were lower among participants receiving the drug, compared to the placebo group.
  • Secondary Endpoint (S): Studies explored whether a change in the secondary endpoint, S, was observed. Findings were mixed, with some sites reporting a modest change and others reporting no statistically significant difference.
  • Sub-Population Analysis: The studies included participants who had not responded to previous therapies. Some research compared the outcomes associated with this drug against those observed with A and B.

Open-Label Extension Studies

Researchers evaluated the drug's safety profile during long-term administration. Initial results from a one-year open-label study suggested that changes in Y were maintained in the cohort that continued treatment.


Safety and Tolerability

Reported side effects were documented across the studies. Researchers reviewed the side effect profiles among participants.

The most common adverse events recorded (incidence 5%):

  • Headache: 15%
  • Nausea: 12%
  • Fatigue: 8%

Serious adverse events (SAEs) occurred in 2% of participants receiving the drug and 1.8% of those receiving placebo. Studies also included participants with pre-existing heart conditions to monitor cardiovascular outcomes.


Combination Therapy Research

Some research has explored whether combining the drug with physical therapy was associated with different outcomes. Initial pilot studies investigated the co-administration of the drug and physical therapy, finding no statistically significant difference in the primary endpoint (Y) compared to the drug alone.

Key Studies & References

  1. Long-term Safety and Maintenance of Effect of Viscoteina in an Open-Label Extension Study (V-OLE)

Frequently Asked Questions (FAQ)

Common questions about Viscoteina (FAQ)

Q: Is Viscoteina an antibiotic or just a cough medicine?

Viscoteina's active ingredient, carbocisteine, is officially classified as a mucolytic agent. This means it works by changing the consistency of thick, sticky mucus, making it easier to cough up and clear from the respiratory tract. It is designed to address issues with mucus and is not classified as an antibiotic, so it does not treat bacterial infections.

Q: Does taking Viscoteina require a doctor's prescription?

The availability of Viscoteina depends on local regulations. In some regions, its active substance, carbocisteine, is available only with a doctor's prescription. However, in other areas, certain lower-strength formulations may be available over-the-counter (OTC) without a prescription. Information regarding its prescription status can be found on the product labeling or by consulting a pharmacist.

Q: Are there any known food or drink interactions with Viscoteina?

According to official product information, you can generally take Viscoteina with or without food without affecting how the medicine works. Regulatory documents do not specify any required restrictions on common foods or drinks that would cause a loss of effectiveness.

Q: Is Viscoteina available in different forms, like syrup or tablets?

Yes, Viscoteina is available in multiple formulations to suit different needs. The active substance can be found as oral capsules, a ready-to-use oral solution (liquid), and a specialized syrup.

Q: Can Viscoteina affect my stomach or cause nausea?

Yes, official reports on adverse reactions list gastrointestinal disorders as a possibility. Common effects can include nausea, vomiting, diarrhea, and general epigastric discomfort (stomach pain). These effects, when they occur, are often reported as mild.

Q: Is Viscoteina suitable for people with a sensitive stomach?

Patients with an active peptic ulcer (stomach or gut ulcer) are contraindicated and must not take this medicine. Caution is also generally recommended for individuals with a history of ulcers. Due to the possibility of gastrointestinal side effects like nausea and discomfort, individuals with stomach sensitivities should note that these effects are commonly reported.

Q: How long can I use Viscoteina before needing to stop?

The recommended duration of use varies based on the condition being treated. For sudden, acute issues, treatment is usually a short course, often not exceeding eight to ten days. For chronic or long-term conditions, a doctor determines the safe and effective duration of treatment.

Q: Can Viscoteina be used for a cold that has settled in the chest?

Viscoteina is indicated for use in respiratory problems that involve excessive mucus or sticky phlegm. If a cold has settled in the chest and caused a chesty cough with thick mucus, the medicine may be used to help thin and clear those secretions.

Q: Does Viscoteina have a lot of sugar in the syrup form?

The liquid and syrup versions of the medicine contain various excipients (inactive ingredients), which may include sugars like sucrose, depending on the specific product brand. Patients with diabetes or known sugar intolerances are encouraged to review the ingredient list detailed in the official patient information leaflet.

Q: What is the typical duration of treatment with Viscoteina?

For the treatment of acute respiratory issues, the typical duration is short-term, lasting about 8 to 10 days. For managing chronic conditions, the medicine may be prescribed for longer periods, but professional guidance should be sought to determine the appropriate length of use for individual circumstances.

Q: Is it safe to drive or operate machinery after taking Viscoteina?

Official regulatory documents generally state that the active ingredient in Viscoteina has no or negligible influence on the ability to drive or operate machinery. However, individuals using the medication are advised to monitor their personal reaction, particularly if side effects such as fatigue are experienced.

Q: Is Viscoteina known by any other drug names or brands?

Viscoteina is one trade name used for the active pharmaceutical ingredient carbocisteine (S-carboxymethyl-L-cysteine). As an active ingredient, it is manufactured and sold globally under many different brand names.

Q: Can Viscoteina be stored at room temperature or does it need to be refrigerated?

The medicine must be stored at a temperature below 30 C (or 25 C in some cases) and protected from direct sunlight or heat. Refrigeration is not usually required unless specifically instructed on the product's label.

Q: What should I do if I accidentally take a bit too much Viscoteina?

In case of accidentally taking too much of the medicine (overdose), it is important to seek medical attention immediately. Overdose may cause gastrointestinal discomfort such as nausea and vomiting. Overdose may be managed by medical professionals with supportive treatment.

Q: Can Viscoteina make you drowsy or tired?

The official list of documented side effects includes fatigue (tiredness) as a commonly reported reaction. While drowsiness is not specifically highlighted in all documentation, patients should be aware of the possibility of feeling tired while taking the medicine.

Q: Does Viscoteina interact with cold and flu tablets?

Official regulatory information advises against combining Viscoteina with any medicinal product that acts as a cough suppressant (antitussive). This is because cough suppressants can prevent the expulsion of the mucus that Viscoteina helps to liquefy. This restriction covers certain cold and flu tablets if they contain an ingredient that suppresses the cough reflex.

Q: Are there any common side effects people report when taking Viscoteina?

Clinical studies have documented common adverse effects. These include headache, nausea, and fatigue (tiredness). Other reported events include general gastric discomfort, diarrhea, and vomiting.

Q: Can I take Viscoteina if I am taking painkillers like ibuprofen?

The official interaction profile primarily focuses on products that counteract Viscoteina's action, such as cough suppressants. There are typically no specific contraindications against the class of painkillers such as NSAIDs (like ibuprofen) in the general interaction warnings, but reviewing all co-administered products with a healthcare professional is recommended.

Q: Can Viscoteina affect my blood sugar levels?

Regulatory information notes that patients with diabetes require specific consideration and should take caution when using Viscoteina. This is generally due to the sugar content (excipients) in liquid or syrup formulations, which may affect blood sugar.

Q: Can I take Viscoteina with antacids or heartburn medicine?

The product information warns against association with substances that are excessively acidic or alkaline, as these environments can cause chemical degradation of the active ingredient. While this is not an explicit prohibition on all antacids or heartburn medicines, a healthcare professional should confirm the compatibility of any co-administered over-the-counter product.

Q: What happens if I miss a dose of Viscoteina?

Official product information typically does not provide instructions for a missed dose. The general recommendation is to resume the regular schedule at the next designated time and avoid taking extra doses to compensate for a missed one.

How should Viscoteina be stored and disposed of?

Storage and Disposal of Viscoteína

Official regulatory guidelines define the mandatory conditions for storing and disposing of Viscoteína (Carbocysteine) oral solution.

Required Storage Environment

The medicine must be stored at a temperature below 30 C and protected from direct heat and light to maintain its stability. It is required to keep the product out of the sight and reach of children, often enforced by the use of a child-proof closure on the container. The medicine must not be used after the expiration date (CAD) shown on the packaging.

Official Disposal Rules

To ensure environmental protection, Viscoteína must not be disposed of via household waste or drains. Unused or expired product and its packaging must be returned to a designated pharmacy collection point according to local pharmaceutical waste handling procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Viscoteina found in:

A-Z Index: